Akova M - Search Results

1

Integrating the time factor into the definition of metastasis of unknown origin.

Barista I, Celik I, Güllü I, Hayran M, Akova M. Barista I, et al. Among authors: akova m. J Natl Cancer Inst. 1996 Jan 3;88(1):51. doi: 10.1093/jnci/88.1.51. J Natl Cancer Inst. 1996. PMID: 8847726 No abstract available.

2

Efficacy of a three-day course of azithromycin in the treatment of community-acquired pneumococcal pneumonia. Preliminary report.

Uzun O, Hayran M, Akova M, Gür D, Akalin HE. Uzun O, et al. Among authors: akova m. J Chemother. 1994 Feb;6(1):53-7. doi: 10.1080/1120009x.1994.11741130. J Chemother. 1994. PMID: 8071680 Clinical Trial.

3

Quinolones in treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin.

Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gür D. Akova M, et al. Antimicrob Agents Chemother. 1993 Sep;37(9):1831-4. doi: 10.1128/AAC.37.9.1831. Antimicrob Agents Chemother. 1993. PMID: 8239591 Free PMC article. Clinical Trial.

4

Treatment of enteric fever with pefloxacin for 7 days versus 5 days: a randomized clinical trial.

Unal S, Hayran M, Tuncer S, Gür D, Uzun O, Akova M, Akalin HE. Unal S, et al. Among authors: akova m. Antimicrob Agents Chemother. 1996 Dec;40(12):2898-900. doi: 10.1128/AAC.40.12.2898. Antimicrob Agents Chemother. 1996. PMID: 9124864 Free PMC article. Clinical Trial.

5

Efficacy of fluconazole in the treatment of upper gastrointestinal candidiasis in neutropenic patients with cancer: factors influencing the outcome.

Akova M, Akalin HE, Uzun O, Hayran M, Tekuzman G, Kansu E, Aslan S, Telatar H. Akova M, et al. Clin Infect Dis. 1994 Mar;18(3):298-304. doi: 10.1093/clinids/18.3.298. Clin Infect Dis. 1994. PMID: 8011807 Clinical Trial.

6

Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis.

Arikan S, Akova M, Hayran M, Ozdemir O, Erman M, Gür D, Unal S. Arikan S, et al. Among authors: akova m. Clin Infect Dis. 1998 Apr;26(4):903-8. doi: 10.1086/513927. Clin Infect Dis. 1998. PMID: 9564473

7

Efficacy of sulbactam-ampicillin for the treatment of severe diabetic foot infections.

Akova M, Ozcebe O, Güllü I, Unal S, Gür D, Akalin S, Tokgözoglu M, Telatar F, Akalin HE. Akova M, et al. J Chemother. 1996 Aug;8(4):284-9. doi: 10.1179/joc.1996.8.4.284. J Chemother. 1996. PMID: 8873834 Clinical Trial.

8

Analysis of a mini-outbreak of methicillin-resistant Staphylococcus aureus in a surgical ward by using arbitrarily primed-polymerase chain reaction.

Cetinkaya Y, Kocagöz S, Hayran M, Uzun O, Akova M, Gürsu G, Unal S. Cetinkaya Y, et al. Among authors: akova m. J Chemother. 2000 Apr;12(2):138-44. doi: 10.1179/joc.2000.12.2.138. J Chemother. 2000. PMID: 10789553

9

Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey.

Akova M, Akan H, Korten V, Biberoğlu K, Hayran M, Unal S, Kars A, Kansu E. Akova M, et al. Int J Antimicrob Agents. 1999 Sep;13(1):15-9. doi: 10.1016/s0924-8579(99)00096-5. Int J Antimicrob Agents. 1999. PMID: 10563400 Clinical Trial.

10

A retrospective review of 228 episodes of infective endocarditis where rheumatic valvular disease is still common.

Cetinkaya Y, Akova M, Akalin HE, Aşçioğlu S, Hayran M, Uzuns O, Aksöyek S, Tokgözoğlu L, Oto A, Kes S, Paşaoğlu I, Unal S. Cetinkaya Y, et al. Among authors: akova m. Int J Antimicrob Agents. 2001 Jul;18(1):1-7. doi: 10.1016/s0924-8579(01)00344-2. Int J Antimicrob Agents. 2001. PMID: 11463520

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

255 results

Search Page

Filters